​

OS Therapies Stock (NYSE:OSTX)

ForecastOwnershipFinancialsChart
OS Therapies by TradingView

Previous Close

$1.70

52W Range

$1.15 - $2.57

50D Avg

$1.64

200D Avg

$1.69

Market Cap

$76.16M

Avg Vol (3M)

$700.62K

Beta

-0.95

Div Yield

-

OSTX Company Profile

OS Therapies Incorporated is a clinical-stage biopharmaceutical company dedicated to identifying, advancing, and commercializing therapeutic solutions for osteosarcoma and other solid tumors within the United States. Its pipeline highlights OST-HER2, a readily available immunotherapy developed for osteosarcoma patients, alongside OST-tunable drug conjugate (OST-tADC). This innovative antibody-drug conjugate technology leverages a modular 'plug-and-play' platform equipped with customizable, pH-sensitive silicone linkers. Established in 2018, OS Therapies Incorporated is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

4

IPO Date

Aug 01, 2024

Website

OSTX Performance

OSTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-28.71B$-6.81M$-4.34M
Net Income$-28.75B$-8.88M$-7.79M
EBITDA$-28.71B$-6.83M$-4.34M
Basic EPS$-0.98$-0.52$-0.39
Diluted EPS$-0.98$-0.52$-0.39

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
COEPCoeptis Therapeutics, Inc.
OTLKOutlook Therapeutics, Inc.
INKTMiNK Therapeutics, Inc.
CRVOCervoMed Inc.
SPRBSpruce Biosciences, Inc.
NRXPNRx Pharmaceuticals, Inc.
IOBTIO Biotech, Inc.
ADAGAdagene Inc.
EQEquillium, Inc.
HOWLWerewolf Therapeutics, Inc.